REACTIVE-2 is assessing the safety and immunological effect of mitazalimab in combination with MesoPher in metastatic pancreatic cancer
Mitazalimab and MesoPher have both achieved positive results in separate Phase 2 clinical studies in pancreatic cancer
Preliminary results of REACTIVE-2 are expected in Q4 2023
Lund, Sweden, and ‘s-Hertogenbosch, the Netherlands, April 26, 2023 – Alligator Bioscience AB (“Alligator”) (Nasdaq Stockholm: ATORX) and Amphera B.V. (“Amphera”) today announce the successful dosing of the last patient in the REACTIVE-2 Phase 1 trial evaluating mitazalimab in combination with MesoPher in patients with metastatic pancreatic cancer.
The open-label, single-center Phase 1 dose finding study is assessing the safety